Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial.
| Title | Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. |
| Publication Type | Journal Article |
| Year of Publication | 2009 |
| Authors | Heron, D. E., Ferris R. L., Karamouzis M., Andrade R. S., Deeb E. L., Burton S., Gooding W. E., Branstetter B. F., Mountz J. M., Johnson J. T., Argiris A., Grandis J. R., & Lai S. Y. |
| Journal | Int J Radiat Oncol Biol Phys |
| Volume | 75 |
| Issue | 5 |
| Pagination | 1493-500 |
| Date Published | 2009 Dec 1 |
| ISSN | 1879-355X |
| Keywords | Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell, Confidence Intervals, Disease-Free Survival, Female, Fluorodeoxyglucose F18, Head and Neck Neoplasms, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Positron-Emission Tomography, Prospective Studies, Quality of Life, Radiation Injuries, Radiopharmaceuticals, Radiosurgery, Radiotherapy Dosage, Remission Induction, Retreatment, Tomography, X-Ray Computed, Tumor Burden |
| Abstract | PURPOSE: To evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) in previously irradiated patients with squamous cell carcinoma of the head and neck (SCCHN).PATIENTS AND METHODS: In this Phase I dose-escalation clinical trial, 25 patients were treated in five dose tiers up to 44 Gy, administered in 5 fractions over a 2-week course. Response was assessed according to the Response Evaluation Criteria in Solid Tumors and [(18)F]-fluorodeoxyglucose standardized uptake value change on positron emission tomography-computed tomography (PET-CT).RESULTS: No Grade 3/4 or dose-limiting toxicities occurred. Four patients had Grade 1/2 acute toxicities. Four objective responses were observed, for a response rate of 17% (95% confidence interval 2%-33%). The maximum duration of response was 4 months. Twelve patients had stable disease. Median time to disease progression was 4 months, and median overall survival was 6 months. Self-reported quality of life was not significantly affected by treatment. Fluorodeoxyglucose PET was a more sensitive early-measure response to treatment than CT volume changes.CONCLUSION: Reirradiation up to 44 Gy using SBRT is well tolerated in the acute setting and warrants further evaluation in combination with conventional and targeted therapies. |
| DOI | 10.1016/j.ijrobp.2008.12.075 |
| Alternate Journal | Int. J. Radiat. Oncol. Biol. Phys. |
| PubMed ID | 19464819 |
| Grant List | P50 CA097190 / CA / NCI NIH HHS / United States |
